Laura J. Zitella

Laura J. Zitella,

MS, RN, ACNP-BC, AOCN

Laura J. Zitella,

MS, RN, ACNP-BC, AOCN

Nurse Practitioner, Associate Clinical Professor, University of California San Francisco

Laura J. Zitella,

MS, RN, ACNP-BC, AOCN

Nurse Practitioner, Associate Clinical Professor, University of California San Francisco

Laura J. Zitella is a nurse practitioner in the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program and Associate Clinical Professor in the Department of Physiological Nursing at the University of California San Francisco. She earned her Master of Science from the University of Illinois in Chicago and holds certifications as an acute care nurse practitioner and an advanced oncology certified nurse.

Her clinical expertise includes patients with hematologic malignancies receiving chemotherapy, immunotherapy, targeted therapy, investigational agents, hematopoietic cell transplantation, and supportive care. She is a prominent educator who has delivered hundreds of educational presentations to national and international audiences and authored numerous peer-reviewed publications, web courses, videos, and book chapters. Laura co-edited the Hematologic Malignancies in Adults textbook, which was awarded an American Medical Writers Association Medical Book Award Honorable Mention.

Laura is actively involved with the Advance Practice Provider Oncology Summit, Advanced Practitioner Society for Hematology and Oncology, the Oncology Nursing Society, and the CLL Society. She serves on medical advisory board of the CLL Society, the Journal of Advanced Practitioner in Oncology editorial board, and several oncology conference planning committees. She is the proud recipient of the ONS Excellence in Medical Oncology award, the DAISY award, and the inaugural Stanford Health Care Advanced Practice Provider of the Year award.

Laura J. Zitella

Laura's Shared Resources

Comprehensive Review of Multiple Myeloma: Advances in Treatment and Ongoing Management

Multiple myeloma (MM) is a malignant clonal plasma cell disorder in the bone marrow and the second-most common hematologic malignancy in adults....
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

Advancements in CAR-T Therapy for RRMM Highlight Crucial Role of Nursing Professionals

The approval of chimeric antigen receptor T-cell (CAR-T) therapies for relapsed/refractory multiple myeloma (RRMM) has significantly advanced treatment options....
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

Lenalidomide Boosts Survival in Patients With Multiple Myeloma

Lenalidomide plays a critical role in managing newly diagnosed multiple myeloma (NDMM), serving as both a first-line and maintenance therapy for patients who are transplant-eligible and ineligible. While effective, optimizing...
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

Provided by an unrestricted grant from

Provided by an unrestricted grant from

Share